Not exact matches
The researchers added that the new compound was designed to reduce toxicity and to improve drug resistance by treating
melanoma cells containing
wild type BRAF as well as mutated BRAF.
For example, vemurafenib is more effective in
melanoma containing BRAFV600E mutation, than
melanoma cells with
wild type BRAF protein.
CCND1, which encodes cyclin D1, is amplified in a number of
melanomas with
wild -
type BRAF and NRAS.